| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abiraterone and castration-resistant prostate cancer
|
Burki, Talha Khan
|
|
2013
|
14 |
2 |
p. e48-
1 p.
|
artikel
|
| 2 |
Ageism and cancer treatment: fallacy not fact
|
Senior, Kathryn
|
|
2013
|
14 |
2 |
p. e48-
1 p.
|
artikel
|
| 3 |
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
|
Gravis, Gwenaelle
|
|
2013
|
14 |
2 |
p. 149-158
10 p.
|
artikel
|
| 4 |
A prognostic model for metastatic renal-cell carcinoma
|
Galsky, Matthew D
|
|
2013
|
14 |
2 |
p. 102-103
2 p.
|
artikel
|
| 5 |
Bevacizumab in breast cancer: fundamental questions remain
|
Miles, David W
|
|
2013
|
14 |
2 |
p. 99-101
3 p.
|
artikel
|
| 6 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
|
Lang, Istvan
|
|
2013
|
14 |
2 |
p. 125-133
9 p.
|
artikel
|
| 7 |
Cancer awareness campaigns: dispelling the myths
|
The Lancet Oncology,
|
|
2013
|
14 |
2 |
p. 97-
1 p.
|
artikel
|
| 8 |
Cancer survivors parks: the changing landscape of cancer
|
Nierengarten, Mary Beth
|
|
2013
|
14 |
2 |
p. 116-
1 p.
|
artikel
|
| 9 |
Correction to Lancet Oncol 2013; 14: 88, 89, 95
|
|
|
2013
|
14 |
2 |
p. e47-
1 p.
|
artikel
|
| 10 |
Correction to Lancet Oncol 2011; 12: 531, 532
|
|
|
2013
|
14 |
2 |
p. e47-
1 p.
|
artikel
|
| 11 |
Detection of other cancers during cervical cancer screening
|
Bennet, Neil
|
|
2013
|
14 |
2 |
p. e49-
1 p.
|
artikel
|
| 12 |
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
|
Kapur, Payal
|
|
2013
|
14 |
2 |
p. 159-167
9 p.
|
artikel
|
| 13 |
EU variation in implementation of tobacco control treaty
|
Kirby, Tony
|
|
2013
|
14 |
2 |
p. 111-
1 p.
|
artikel
|
| 14 |
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
|
Heng, Daniel YC
|
|
2013
|
14 |
2 |
p. 141-148
8 p.
|
artikel
|
| 15 |
Homing in on new cancer drug targets?
|
Senior, Kathryn
|
|
2013
|
14 |
2 |
p. e49-
1 p.
|
artikel
|
| 16 |
International Rare Cancers Initiative
|
Keat, Nicola
|
|
2013
|
14 |
2 |
p. 109-110
2 p.
|
artikel
|
| 17 |
Pathobiology of chemotherapy-induced hair loss
|
Paus, Ralf
|
|
2013
|
14 |
2 |
p. e50-e59
nvt p.
|
artikel
|
| 18 |
Prostate cancer therapy: going forwards by going backwards
|
Sweeney, Christopher
|
|
2013
|
14 |
2 |
p. 104-105
2 p.
|
artikel
|
| 19 |
Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database
|
Rosenblatt, Eduardo
|
|
2013
|
14 |
2 |
p. e79-e86
nvt p.
|
artikel
|
| 20 |
Renal-cell carcinoma: a step closer to a new classification
|
Choueiri, Toni K
|
|
2013
|
14 |
2 |
p. 105-107
3 p.
|
artikel
|
| 21 |
Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial
|
Carozzi, Francesca
|
|
2013
|
14 |
2 |
p. 168-176
9 p.
|
artikel
|
| 22 |
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
|
Farley, John
|
|
2013
|
14 |
2 |
p. 134-140
7 p.
|
artikel
|
| 23 |
Targeting developmental pathways in children with cancer: what price success?
|
Gore, Lia
|
|
2013
|
14 |
2 |
p. e70-e78
nvt p.
|
artikel
|
| 24 |
54th ASH Annual Meeting
|
Collingridge, David
|
|
2013
|
14 |
2 |
p. 112-
1 p.
|
artikel
|
| 25 |
The Big Squeeze
|
Kalager, Mette
|
|
2013
|
14 |
2 |
p. 115-
1 p.
|
artikel
|
| 26 |
The Yellow World
|
Cantor, Abi
|
|
2013
|
14 |
2 |
p. 114-115
2 p.
|
artikel
|
| 27 |
Toilet humour
|
Cagney, Hannah
|
|
2013
|
14 |
2 |
p. 113-
1 p.
|
artikel
|
| 28 |
Towards individualised treatment in ovarian cancer
|
Mahner, Sven
|
|
2013
|
14 |
2 |
p. 101-102
2 p.
|
artikel
|
| 29 |
Tragedy+time=comedy
|
Budd, Helen
|
|
2013
|
14 |
2 |
p. 114-
1 p.
|
artikel
|
| 30 |
Triage of HPV-positive women in cervical cancer screening
|
Wentzensen, Nicolas
|
|
2013
|
14 |
2 |
p. 107-109
3 p.
|
artikel
|
| 31 |
2-weekly versus 3-weekly docetaxel for prostate cancer
|
Nanus, David M
|
|
2013
|
14 |
2 |
p. 98-99
2 p.
|
artikel
|
| 32 |
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
|
Kellokumpu-Lehtinen, Pirkko-Liisa
|
|
2013
|
14 |
2 |
p. 117-124
8 p.
|
artikel
|
| 33 |
Which drug, and when, for patients with BRAF-mutant melanoma?
|
Jang, Sekwon
|
|
2013
|
14 |
2 |
p. e60-e69
nvt p.
|
artikel
|
Tijdschrift beschrijving